Hepatitis C, Chronic
Conditions
Keywords
Interferon Sparing, Directly Acting Antiviral, Ribavarin Sparing
Brief summary
Background: \- GS-7977, GS-5885, GS-9669, and GS-9451 are new drugs for treating hepatitis C virus (HCV) infection. GS-7977 may help treat the infection when used with other treatments like interferon therapy. GS-5885, and GS-9669, and GS-9451 also lower the amount of HCV in the body. Researchers want to see whether GS-7977 can be combined with any of the other three drugs to treat HCV infection. Some participants will take GS-7977 and GS-5885. Others will take GS-7977, GS-5885 and GS-9669 or GS-7977, GS-5885 and GS-9451. Objectives: \- To see whether GS-7977 with GS-5885 alone or in combination with either GS-9669 or 9451 can be used to treat HCV infection. Eligibility: Individuals at least 18 years of age who have chronic HCV infection and have never been treated for it. Individuals at least 18 years of age who have chronic HCV infection and have not responded to interferon therapy. Individuals at least 18 years of age who have chronic HCV infection with advanced liver disease and have never been treated for HCV Design: Participants will be screened with a physical exam and medical history. Blood samples will be collected. A liver biopsy may also be performed. Some participants will take the two study drugs and some will take three study drugs. Those who take GS-7977 and GS-5885 will have one daily tablet named fixed dose combination or FDC. Those who take GS-7977 and CS-9669 will have three daily tablets taken once daily. Those who take GS-7977 and GS-5885 and GS-9451 will take 2 pills once a day. GS-7977 and GS-5885 will be combined in one pill and GS-9451 will be in another pill. Treatment will be monitored with frequent blood tests. These tests will check liver function and the level of HCV infection. Participants may have other blood tests as needed for treatment. Participants will have 4, 6 or 12 weeks of treatment depending on which study drugs are scheduled to take. After they complete their schedule, they will stop treatment with the study drugs. They may also have another liver biopsy. Participants will have regular follow-up visits over the next 48 weeks. They will have physical exams and provide blood samples....
Detailed description
Chronic hepatitis C virus (HCV) infection is a major public health problem with an estimated 180 million people infected worldwide. In the United States an estimated 4.1 million people are infected, and HCV is the principal cause of death from liver disease and leading indication for liver transplantation. While treatment with ribavirin (RBV) and pegylated interferon (PEG) in combination with boceprevir/telaprevir is the currently recommended therapy for chronic HCV infection and has superior cure rates compared to PEG+RBV alone in HCV monoinfected patients, treatment is still associated with a high incidence of adverse events (AEs), discontinuations, and poor cure rates in several populations. Recent studies have demonstrated that the use of a combination of antivirals, which target HCV without interferon (IFN), can cure HCV without additional toxicities. However, the determinants of response to IFN-free regimens have not been established. This is an open label study to assess the safety, tolerability, and efficacy of treatment with GS-7977 with GS-5885, alone or in combination with GS-9669 and/or GS-9451 (selective HCV nucleotide NS5B, NS5A, nonnucleotide NS5B and NS3 inhibitors, respectively) in HCV infected treatment naive and treatment experienced patients with early and advanced liver disease. The findings from this study will aid in our understanding of determinants of response to an IFN-free regimen in HCV infected patients for both patients with early and advanced liver disease as well as in patients who are treatment naive and those who have been treated before for HCV.
Interventions
Sponsors
National Institute of Allergy and Infectious Diseases (NIAID)
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* INCLUSION CRITERIA: 1. Eighteen years of age or older at screening. 2. Female study participants with childbearing potential (as defined below) and all males must be willing to practice either: * Abstinence from sexual intercourse or * One or more forms of effective barrier contraception throughout dosing and for 30 days following the last dose. This cannot include hormonal contraception for female subjects. Effective forms of barrier contraception include: * a male condom with spermicide * use by female sexual partner of a female condom with spermicide Non-childbearing potential (i.e., physiologically incapable of becoming pregnant) includes any female who: * Has had a hysterectomy or * Has had a bilateral oophorectomy (ovariectomy) or * Is post-menopausal (a demonstration of a total cessation of menses for greater than or equal to1 year) * Has had a bilateral tubal ligation or fallopian tube inserts 3. Chronic HCV GT-1 or GT-4 infection as documented by greater than or equal to 1 measurement of serum HCV RNA greater than or equal to 2,000 international units per milliliter during screening and at least one of the following: * A positive anti-HCV antibody, HCV RNA, or HCV genotype test result greater than or equal to 12 months prior to the baseline (day 0) visit together with current positive HCV RNA and anti-HCV antibody test results or * Positive HCV RNA test and anti-HCV antibody test results together with a liver biopsy consistent with chronic HCV infection or a liver biopsy performed before enrollment with evidence of chronic hepatitis C infection disease, such as the presence of fibrosis. 4. Group A may include up to 20% of subjects with compensated cirrhosis. Group B and C may only include subjects with absence of cirrhosis. Group D, D-ReTx & E may include subjects with compensated cirrhosis. Group F may only include patients with advanced liver disease (historic Metavir or HAI Stage 3 or 4 or ISHAK Stage 4, 5 or 6 or cirrhosis as defined below) Group G and H may only include those with absence of cirrhosis and HAI Stage 0-2 or FibroTest as below. Cirrhosis is defined as any one of the following: 1. Any biopsy showing cirrhosis. 2. A FibroTest(r) score of greater than or equal to 0.75 AND an AST: platelet ratio (APRI) of \> 2 performed within 12 months of screening. Liver imaging within 6 months of Day 0 to exclude hepatocellular carcinoma (HCC) is required in patients with cirrhosis. Absence of cirrhosis is defined as one of the following: 1. A liver biopsy performed within 36 calendar months of screening showing absence of cirrhosis. 2. A FibroTest(r) score of \< 0.48 AND APRI of \< 1 performed within 6 months of screening. This would also qualify a subject for Group G and H as having Stage 0-2 disease in the absence of a liver biopsy. In the absence of a definitive diagnosis of presence or absence of cirrhosis by the above criteria, a liver biopsy is required (for Groups B, C, G and H). 5. Ability to communicate effectively with the study investigator and other key personnel. 6. Willing to give written informed consent and comply with the study restrictions and requirements. 7. Opioid-dependent individuals must be participating in a supervised treatment program. 8. Subjects must have an external primary care doctor (outside of the CC and the NIH) for their medical management.
Exclusion criteria
1. Current or prior history of any of the following: * Clinically-significant illness (other than HCV) or any other major medical disorder that may interfere with subject treatment, assessment or compliance with the protocol; subjects currently under evaluation for a potentially clinically-significant illness (other than HCV) are also excluded. * Gastrointestinal disorder or post operative condition that could interfere with the absorption of the study drug. * Poor venous access interfering with required study blood collection. * Clinical hepatic decompensation (i.e., ascites, encephalopathy or variceal hemorrhage). * Solid organ transplantation. * Significant pulmonary disease, significant cardiac disease or porphyria. * Unstable psychiatric disease (Subjects with psychiatric illness that is well-controlled on a stable treatment regimen or currently not requiring medication may be included). * Any malignancy or its treatment that in the opinion of the PI may cause ongoing interference with host immunity; subjects under evaluation for malignancy are not eligible. * Significant drug allergy (such as anaphylaxis or hepatotoxicity). * Substance abuse, which in the opinion of the investigator is likely to interfere with medication adherence or study compliance. * Lactose allergy, patients with lactose intolerance will be evaluated on a case-by-case basis. 2. Positive test results at screening for hepatitis B virus (HBV) surface antigen (HBsAg), HBV DNA (if medically indicated) or anti-HIV antibody (unless previously treated on 13-I-0159). 3. Prior exposure to any direct-acting antivirals for HCV infection, except for patients who were previously treated studies 11-I-0258, 13-I-1059 or this study enrolling in Group D. 4. History of clinically significant chronic liver disease due to other etiology (e.g., hemochromatosis, autoimmune hepatitis, Wilson s disease, alpha 1-antitrypsin deficiency, alcoholic liver disease, \> moderate non-alcoholic steatohepatitis and toxin exposures). 5. Use of herbal/natural remedies for potential benefit to the liver within 21 Days of Day 0. 6. History of ascites, variceal hemorrhage, hepatic encephalopathy, or conditions consistent with decompensated liver disease. 7. Screening or baseline ECG with clinically significant ECG findings, or a personal/first degree relative history of Torsade de pointes. 8. Abnormal hematological and biochemical parameters at screening, including: * Neutrophil count less than 750 cells per cubic millimeter. * Hemoglobin level \< 9 g/dL. If Hgb \< 11g/dL in women and \< 12 g/dL in men other causes of anemia should be excluded as medically indicated. * Platelet count less than or equal to 50,000 cells per cubic millimeter. * Estimated glomerular filtration rate less than 50 milliliter/min/1.73m(2). * ALT or AST level greater than or equal to 10 times upper limit of normal (ULN). * Serum lipase level greater than or equal to 1.5 times upper limit of normal (ULN)at screening or during the screening period in a patient with symptoms consistent with pancreatitis. * Total bilirubin level greater than or equal to 2.0 times upper limit of normal (ULN), except in subjects with Gilbert s syndrome. * Albumin level less than or equal to 3.0 grams per deciliter in patients without cirrhosis, albumin less than or equal to 2.8 g/dL in cirrhotic patients. 9. Poorly controlled diabetes mellitus indicated by hemoglobin A1C greater than 9% at screening. 10. Donation or loss of blood of greater than 400 milliliter within 8 weeks prior to the first dose of the study drugs. 11. Known hypersensitivity to GS-5885, GS-7977, GS-9669, GS-9451 or formulation excipients. 12. Pregnant/Breastfeeding women. 13. Need for use of the following medications from 21 days prior to the start of study drugs through the end of treatment (unless otherwise specified): * Hematologic stimulating agents (e.g. erythropoiesis-stimulating agents (ESAs); granulocyte colony stimulating factor (GCSF); thrombopoietin (TPO) mimetics). * Chronic systemic immunosuppressants including, but not limited to, corticosteroids (prednisone equivalent of greater than 10 milligrams per day for greater than 2 weeks), azathioprine, or monoclonal antibodies (e.g., infliximab). * Investigational agents or devices for any indication. * Medications for disease conditions excluded from the protocol (e.g., active cancer, transplantation) are not listed under this Concomitant Medication section and are disallowed in the study. * Concomitant use of certain medications or herbal/natural supplements per PI discretion expected to result in pharmacokinetic interactions resulting in increases or decreases in exposure of study drug(s). 14. Co-enrollment Guidelines: Co-enrollment in other clinical trials is restricted, other than enrollment in observational studies. Study staff should be notified of co-enrollment status, as it may require prior approval of the investigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The Proportion of Subjects Who Achieve Sustained Viral Response (SVR12) 12 Weeks After the Stop of Treatment Drugs | 12 weeks after stop of treatment | The primary outcome was the proportion of patients with sustained viral response measured 12 weeks after the stop of treatment. The viral response was assessed by serum HCV RNA concentrations lower than 43 IU/mL - the lower limit of quantification. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| A: HCV GT-1, tx Naive, 12 Wks Sofosbuvir/Ledipasvir Oral treatment with Sofosbuvir 400mg (GS-7977) and Ledipasvir 90mg (GS-5885), once daily, for 12 weeks in HCV genotype 1, treatment naïve patients | 20 |
| B: HCV GT-1, tx Naive, 6 Wks Sofosbuvir/Ledipasvir/GS-9669 Oral treatment with Sofosbuvir 400mg (GS-7977), Ledipasvir 90mg (GS-5885), GS-9669 500mg, once daily, for 6 weeks in HCV genotype 1, treatment naïve patients | 20 |
| C: HCV GT-1, tx Naive, 6 Wks Sofosbuvir/Ledipasvir/GS-9451 Oral treatment with Sofosbuvir 400mg (GS-7977), Ledipasvir 90mg (GS-5885), GS-9451 80mg, once daily, for 6 weeks in HCV genotype 1, treatment naïve patients | 20 |
| D Retx: HCV GT-1, Re-Treatment, 12 Wks Sofosbuvir, Ledipasvir Oral treatment with Sofosbuvir 400mg (GS-7977) and Ledipasvir 90mg (GS-5885), once daily, 12 weeks in HCV genotype 1 subjects who failed HCV therapy in Arm B or Arm G or Arm H | 34 |
| D: HCV GT-1, Tx-relapsed, 12 Wks Sofosbuvir/Ledipasvir Oral treatment with Sofosbuvir 400mg (GS-7977) and Ledipasvir 90mg (GS-5885), once daily, for 12 weeks in HCV genotype 1, treatment-relapsed patients who previously received Sofosbuvir plus Ribavirin | 14 |
| E: HCV GT-4, tx Naive/Expd, 12 Wks Sofosbuvir/Ledipasvir Oral treatment with Sofosbuvir 400mg (GS-7977) and Ledipasvir 90mg (GS-5885), once daily, 12 weeks in HCV genotype 4 treatment naïve subjects and interferon treament experienced subjects | 21 |
| F: HCV GT-1, tx Naive/Expd 6 Wks Sofosbuvir/Ledipasvir/GS-9451 Oral treatment with Sofosbuvir 400mg (GS-7977) and Ledipasvir 90mg (GS-5885) and GS-9451 80mg, once daily, 6 weeks in HCV genotype 1 treatment naïve and treatment experienced subjects with advanced liver disease | 50 |
| G: HCV GT-1, tx Naive, 4 Wks Sofosbuvir, Ledipasvir, GS-9451 Oral Treatment with Sofosbuvir 400mg (GS-7977) and Ledipasvir 90mg (GS-5885) with GS-9451 80mg, once daily, 4 weeks in HCV genotype 1 treatment naïve subjects with early stage liver disease | 25 |
| H: HCV GT-1, tx Naive, 4 Wks Sofos/Ledip/GS-9451/GS-9669 Oral Treatment with Sofosbuvir 400mg (GS-7977) and Ledipasvir 90mg (GS-5885) with GS-9451 80mg, and GS-9669 250mg, once daily, 4 weeks in HCV genotype 1 treatment naïve subjects with early stage liver disease | 25 |
| Total | 229 |
Baseline characteristics
| Characteristic | Total | B: HCV GT-1, tx Naive, 6 Wks Sofosbuvir/Ledipasvir/GS-9669 | C: HCV GT-1, tx Naive, 6 Wks Sofosbuvir/Ledipasvir/GS-9451 | A: HCV GT-1, tx Naive, 12 Wks Sofosbuvir/Ledipasvir | D Retx: HCV GT-1, Re-Treatment, 12 Wks Sofosbuvir, Ledipasvir | D: HCV GT-1, Tx-relapsed, 12 Wks Sofosbuvir/Ledipasvir | E: HCV GT-4, tx Naive/Expd, 12 Wks Sofosbuvir/Ledipasvir | F: HCV GT-1, tx Naive/Expd 6 Wks Sofosbuvir/Ledipasvir/GS-9451 | G: HCV GT-1, tx Naive, 4 Wks Sofosbuvir, Ledipasvir, GS-9451 | H: HCV GT-1, tx Naive, 4 Wks Sofos/Ledip/GS-9451/GS-9669 |
|---|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 24 Participants | 1 Participants | 1 Participants | 1 Participants | 7 Participants | 3 Participants | 2 Participants | 2 Participants | 1 Participants | 6 Participants |
| Age, Categorical Between 18 and 65 years | 205 Participants | 19 Participants | 19 Participants | 19 Participants | 27 Participants | 11 Participants | 19 Participants | 48 Participants | 24 Participants | 19 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 5 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 3 Participants | 1 Participants | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 223 Participants | 20 Participants | 20 Participants | 19 Participants | 34 Participants | 14 Participants | 21 Participants | 46 Participants | 24 Participants | 25 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 2 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 169 Participants | 19 Participants | 18 Participants | 15 Participants | 28 Participants | 13 Participants | 9 Participants | 29 Participants | 19 Participants | 19 Participants |
| Race (NIH/OMB) More than one race | 4 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 2 Participants | 1 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 5 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 2 Participants | 1 Participants | 1 Participants |
| Race (NIH/OMB) White | 49 Participants | 1 Participants | 2 Participants | 3 Participants | 5 Participants | 1 Participants | 11 Participants | 17 Participants | 4 Participants | 5 Participants |
| Sex: Female, Male Female | 63 Participants | 8 Participants | 4 Participants | 6 Participants | 6 Participants | 1 Participants | 7 Participants | 17 Participants | 8 Participants | 6 Participants |
| Sex: Female, Male Male | 166 Participants | 12 Participants | 16 Participants | 14 Participants | 28 Participants | 13 Participants | 14 Participants | 33 Participants | 17 Participants | 19 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk | EG007 affected / at risk | EG008 affected / at risk |
|---|---|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — | — / — | — / — | — / — | — / — | — / — | — / — |
| other Total, other adverse events | 17 / 20 | 20 / 20 | 20 / 20 | 34 / 34 | 14 / 14 | 17 / 21 | 48 / 50 | 24 / 25 | 25 / 25 |
| serious Total, serious adverse events | 0 / 20 | 0 / 20 | 2 / 20 | 1 / 34 | 1 / 14 | 0 / 21 | 2 / 50 | 0 / 25 | 1 / 25 |
Outcome results
Primary
The Proportion of Subjects Who Achieve Sustained Viral Response (SVR12) 12 Weeks After the Stop of Treatment Drugs
The primary outcome was the proportion of patients with sustained viral response measured 12 weeks after the stop of treatment. The viral response was assessed by serum HCV RNA concentrations lower than 43 IU/mL - the lower limit of quantification.
Time frame: 12 weeks after stop of treatment
Population: Subjects who received treatment drugs per arm as listed in the Outcome Measure Description
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| A: HCV GT-1, tx Naive, 12 Wks Sofosbuvir/Ledipasvir | The Proportion of Subjects Who Achieve Sustained Viral Response (SVR12) 12 Weeks After the Stop of Treatment Drugs | 100 percentage of subjects |
| B: HCV GT-1, tx Naive, 6 Wks Sofosbuvir/Ledipasvir/GS-9669 | The Proportion of Subjects Who Achieve Sustained Viral Response (SVR12) 12 Weeks After the Stop of Treatment Drugs | 95 percentage of subjects |
| C: HCV GT-1, tx Naive, 6 Wks Sofosbuvir/Ledipasvir/GS-9451 | The Proportion of Subjects Who Achieve Sustained Viral Response (SVR12) 12 Weeks After the Stop of Treatment Drugs | 95 percentage of subjects |
| D Retx: HCV GT-1, Re-Treatment, 12 Wks Sofosbuvir, Ledipasvir | The Proportion of Subjects Who Achieve Sustained Viral Response (SVR12) 12 Weeks After the Stop of Treatment Drugs | 91.2 percentage of subjects |
| D: HCV GT-1, Tx-relapsed, 12 Wks Sofosbuvir/Ledipasvir | The Proportion of Subjects Who Achieve Sustained Viral Response (SVR12) 12 Weeks After the Stop of Treatment Drugs | 100 percentage of subjects |
| E: HCV GT-4, tx Naive/Expd, 12 Wks Sofosbuvir/Ledipasvir | The Proportion of Subjects Who Achieve Sustained Viral Response (SVR12) 12 Weeks After the Stop of Treatment Drugs | 95 percentage of subjects |
| F: HCV GT-1, tx Naive/Expd 6 Wks Sofosbuvir/Ledipasvir/GS-9451 | The Proportion of Subjects Who Achieve Sustained Viral Response (SVR12) 12 Weeks After the Stop of Treatment Drugs | 76 percentage of subjects |
| G: HCV GT-1, tx Naive, 4 Wks Sofosbuvir, Ledipasvir, GS-9451 | The Proportion of Subjects Who Achieve Sustained Viral Response (SVR12) 12 Weeks After the Stop of Treatment Drugs | 40 percentage of subjects |
| H: HCV GT-1, tx Naive, 4 Wks Sofos/Ledip/GS-9451/GS-9669 | The Proportion of Subjects Who Achieve Sustained Viral Response (SVR12) 12 Weeks After the Stop of Treatment Drugs | 20 percentage of subjects |